Sali e Derivati degli API

<p>Impurity Tiotropium bromide EP impurity C<br>Applications (1R,3S,5S)-3-(2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy)-8,8-dimethyl-8-azabicyclo[3.2.1]oct-6-en-8-ium Bromide is an impurity in the synthesis of Tiotropium Bromide (T444850), a muscarinic receptor antagonist. Bronchodilator.<br>References Haddad, E.-B., et al.: Mol. Pharmacol., 45, 899 (1994); Donohue, J. F., et al.: Chest, 122, 47 (2002); Profita, M., et al.: Allergy, 60, 1361 (2005); Dusser, D., et al.: Eur. Respir. J., 27, 547 (2006);<br></p>

<p>Applications Ivermectin B1a-D2 is a deuterium labelled analogue of Ivermectin B1a (I940815), which is a major component of Ivermectin (I940800), a semi-synthetic derivative of Abamectin; consists of a mixture of not less than 80% component B1a and not more than 20% component B1b. Antihelmintic (Onchocerca). An invitro inhibitor of SARS-CoV-2/ Covid-19.<br>References Chabala, J.C., et al.: J. Med. Chem., 23, 1134 (1980); Campbell, W.C., et al.: Science, 221, 823 (1983); Bennett, J.L., et al.: Parasitol. Today, 4, 226 (1988); Plaisier, A.P., et al.: J. Infect. Dis., 172, 204 (1995);; Caly, L., et al.: Antivir. Res., 178<br></p>

<p>Applications Uricosuric.<br>References McKinney, S.E., et al.: J. Pharmacol. Exp. Ther., 102, 208 (1951), Israili, Z.H., et al.: J. Med. Chem., 15, 709 (1972), Al-Badr, A.A., et al.: Anal. Profiles Drug Subs., 10, 639 (1981), Cunningham, R.F., et al.: Clin. Pharmacokinet., 6, 135 (1981),<br></p>

<p>Applications Boc-L-Nitroarginine, can be used in peptide chemistry. It has been also shown to act as NO synthase inhibitor, and thus used in the study of The effects of methylene blue (MB) for treatment of sepsis induced by bowel perforation.<br>References Galili, Y. Euro. surg. Rese. vol. 29, P:390-395 (19997);<br></p>

<p>Applications Riociguat is used in the treatment for pulmonary hypertension.<br>References Frey, R. et al.: J. Clin. Pharmacol., 51, 1051 (2011);<br></p>

<p>Applications Edaravone D5 is the labelled compound of Edaravone(E335000). synthesized and used for relative quant. anal. of oligosaccharides by mass spectrometry (MS). Edaravone inhibits the disease activity in rheumatoid arthritis. Edaravone can significantly enhance IR flap viability and protect flap vessels, which is related to scavenging oxygen free radicals, reducing the consumption of SOD, reducing the extent of lipid peroxidation and inflammation, and protecting functional structure of vessels in the early stages of reperfusion. It also shows protective effects against STZ-induced cognitive impairment, oxidative stress, cholinergic dysfunction and altered protein expressions. Its acts like a free radical scavenger, decreased apoptotic cell death, oxidative damage to DNA and lipids, and angiogene<br>References Zhang, Ping, et al.: Anal. Biochem., 418, 1(2011)<br></p>

<p>Applications An immunosuppressive. Inhibits T and B cell proliferation. Activity is attributed mainly to its metabolite, a malononitrile derivative, which is beleived to inhibit dihydroorotate dehydrogenase as well as several protein tyrosine kinases.This compound is suitable for dihydroorotate dehydrogenase (DHODH) related research.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Vrenken, T., et al.: J. Hepatol., 49, 799 (2008), Mazzucco, G., et al.: Clin. Nephrol., 70, 163 (2008), Davies, M., et al.: J. Med. Chem., 52, 2683 (2009),<br></p>

<p>Applications Riociguat-13C-d3 is the labelled analogue of Riociguat (R520000), which is used in the treatment for pulmonary hypertension.<br>References Frey, R. et al.: J. Clin. Pharmacol., 51, 1051 (2011);<br></p>

<p>Applications Nonionic, injectable radio-contrast medium. Diagnostic aid (radiopaque medium).<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Muetzel, W., et al.: Am.J. Neuroradiol., 4, 350 (1983), Dawson, P., et al.: Acta Radiol. Diagn., 25, 253 (1984),<br></p>

<p>Applications Tacrolimus Hydrate is a disease-modifying antirheumatic drugs (DMARDs)<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Ogasawara, M., et al.: Mod. Rheumatol., 22, 831-836 (2012)<br></p>

<p>Applications A novel antithrombotic agent. A highly potent and selective, direct FXa inhibitor.<br>References Ansell, J., et al.: Drugs, 64, 1 (2004), Eriksson, B., et al.: J. Thromb. Haemost., 3, 103 (2005), Kubitza, D., et al.: Clin. Pharmacol. Ther., 78, 412 (2005),<br></p>